Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways
- 7 September 2024
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 135, 156022
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82072685)
- Zhejiang University Student Science and Technology Innovation Activity Plan (2023R413059)
- Ministry of Science and Technology of the People's Republic of China (2023YFE0118000)
This publication has 25 references indexed in Scilit:
- Role of the GLP2–Wnt1 axis in silicon-rich alkaline mineral water maintaining intestinal epithelium regeneration in piglets under early-life stressCellular and Molecular Life Sciences, 2024
- Predicting very early recurrence in intrahepatic cholangiocarcinoma after curative hepatectomy using machine learning radiomics based on CECT: A multi-institutional studyComputers in Biology and Medicine, 2023
- Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposingBiomedicine & Pharmacotherapy, 2023
- Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progressionHepatology, 2022
- A Transcriptomic Signature for Risk‐Stratification and Recurrence Prediction in Intrahepatic CholangiocarcinomaHepatology, 2021
- Very Early Recurrence After Liver Resection for Intrahepatic CholangiocarcinomaJAMA Surgery, 2020
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersJAMA Oncology, 2019
- Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectivesCancer Treatment Reviews, 2019
- Molecular evidence for better efficacy of hypocrellin A and oleanolic acid combination in suppression of HCC growthEuropean Journal of Pharmacology, 2019
- Plants as sources of natural and recombinant anti-cancer agentsBiotechnology Advances, 2018